The MEU is a UK leader in Early Phase clinical trials in Manchester. We have considerable expertise in SAD and MAD trials. The emergence of hybrid designs, including patient cohorts, has allowed the MEU to provide a complete solution for clients seeking a single site solution for their Early Phase programme.
The MEU is well-equipped to undertake large single centre early phase healthy volunteer clinical trials and specialist respiratory trials including Asthma, COPD, Cystic Fibrosis, Allergy, Dermatology, Inflammatory, Cardiovascular and Diabetes. Our ever-expansive portfolio facilitates the MEU to undertake Phase I studies in many other therapeutic areas.
We are home to state-of-the art, hospital-based facilities including 36 inpatient beds with cardiac and telemetry monitoring, a Phase I MHRA accredited pharmacy, clinical assessment suite and numerous outpatient/consultant rooms.
Our bespoke database and trial management system I.C.A.R.U.S. assists recruitment of the right patient to the right study, facilitating rapid enrolment, allowing us to meet our clients’ timelines. Our database currently hosts over 38,000 patients and healthy volunteers.
The MEU is now at the forefront of testing new climate-friendly inhalers to ensure they are safe and effective for large populations worldwide and to support the transition towards low GWP propellants in devices used for inhaled drug delivery.
The MEU is an MHRA Phase I accredited unit and has been part of the scheme since its inception. This ensures that our studies are conducted to the highest standards in terms of both safety and quality.
MEU have held MHRA Phase I accreditation since July 2009 with the latest inspection being 2022.
Over the last 13 years and 6 inspections, we are proud to have had No Critical or Major findings:
